These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35810692)

  • 1. Cellular landscaping of cisplatin resistance in cervical cancer.
    Bhattacharjee R; Dey T; Kumar L; Kar S; Sarkar R; Ghorai M; Malik S; Jha NK; Vellingiri B; Kesari KK; Pérez de la Lastra JM; Dey A
    Biomed Pharmacother; 2022 Sep; 153():113345. PubMed ID: 35810692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Long Non-coding RNA (LncRNA) in the Pathogenesis of Chemotherapy Resistance in Cervical Cancer: Diagnostic and Prognostic Approach.
    Modabber N; Mahboub SS; Khoshravesh S; Karimpour F; Karimi A; Goodarzi V
    Mol Biotechnol; 2024 Oct; 66(10):2751-2768. PubMed ID: 37804407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancer of mRNA Decapping protein 4 (EDC4) interacts with replication protein a (RPA) and contributes to Cisplatin resistance in cervical Cancer by alleviating DNA damage.
    Wu X; Zhong Y; Chen Q; Zhang X; Zhang H
    Hereditas; 2020 Oct; 157(1):41. PubMed ID: 33054858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
    Mehta H; Ambele MA; Mokgautsi N; Moela P
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
    Li R; Liu GZ; Luo SY; Chen R; Zhang JX
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
    Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.
    Okada T; Murata K; Hirose R; Matsuda C; Komatsu T; Ikekita M; Nakawatari M; Nakayama F; Wakatsuki M; Ohno T; Kato S; Imai T; Imamura T
    Sci Rep; 2013 Oct; 3():2899. PubMed ID: 24113164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
    Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
    Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRSK1 confers cisplatin resistance in cervical cancer cells via regulation of mitochondrial respiration.
    Liu G; Li L; Shang D; Zhou C; Zhang C
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8803-8815. PubMed ID: 37140697
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Chi C; Mao M; Shen Z; Chen Y; Chen J; Hou W
    Hum Gene Ther; 2018 Dec; 29(12):1438-1448. PubMed ID: 29896986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.
    Wang Z; Li F; He S; Zhao L; Wang F
    Gene; 2022 Jan; 809():146003. PubMed ID: 34648915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
    Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
    Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Su J; Zhang F; Li X; Liu Z
    Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling.
    Xiong Y; Sun F; Dong P; Watari H; Yue J; Yu MF; Lan CY; Wang Y; Ma ZB
    J Exp Clin Cancer Res; 2017 Apr; 36(1):48. PubMed ID: 28399926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [EBF1 Promotes the Sensitivity of Cervical Cancer Cells to Cisplatin via Activating FBN1 Transcription].
    Shen NN; Lin JH; Liu PP
    Mol Biol (Mosk); 2023; 57(3):503-504. PubMed ID: 37326054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyphyllin I Sensitizes Cisplatin-Resistant Human Cervical Cancer Cells to Cisplatin Treatment.
    Zhang L; Liu W; Li Y; Fu Y; Xu C; Yu M
    Nutr Cancer; 2024; 76(7):656-665. PubMed ID: 38733116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer.
    Zhu X; Long L; Xiao H; He X
    Dis Markers; 2021; 2021():1544784. PubMed ID: 34567283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance.
    Leisching G; Loos B; Botha M; Engelbrecht AM
    J Transl Med; 2015 Oct; 13():328. PubMed ID: 26474854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
    Shu XR; Wu J; Sun H; Chi LQ; Wang JH
    Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
    Zhang WY; Liu YJ; He Y; Chen P
    J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.